Talphera Inc. (TLPH)

[MTH4]

From Top 10 Holder of ACRX from Adam F. Article ACRX has potential of $36.92 share price
.

Hello Everyone, This very exciting part below from the Adam Feuerstein article shows that a top 10 holder of ACRX sees the potential of an approximate $36.92 share price on ACRX. When Adam referred to market cap of 400 million on ACRX that would be based on the share price of $9.23 on ACRX which is based on $100 million in Zalviso sales. With the top 10 holder of ACRX projecting 30% and $400 million in sales would put the potential stock price of ACRX at 4 times higher or $36.92. Also consider that this does not include the additional possible revenue from the partner pursuing Zalviso approval in Europe. I am so happy I am still holding my shares and recently added to my position since we have the potential of a very huge winner for ACRX with the approval of Zalviso.

I spoke to a Top 10 holder of AcelRx. He believes Zalviso can capture 30% of the IV PCA post-op surgical market in U.S. hospitals with parity pricing, generating peak sales of $400 million. Upside revenue in the U.S. could come from broader use of Zalviso beyond the surgical setting, i.e. to control moderate-to-severe pain. The stock's current market cap of $400 million only bakes in about $100 million in Zalviso sales -- too low, he believes. AcelRx has a partner pursuing Zalviso approval in Europe, so any revenue generated there is also upside to these estimates.